Nanosonics Ltd shares have fallen almost 30% over the past year, but according to the team at RBC Capital Markets, they could be primed for a recovery.
First, let's look at the company's most recent news – its FY26 financial results and the announcement of a share buyback.
The company's revenue was up 3% to $203.9 million, while EBIT was $16 million, down 10%.
The company had no debt and cash on hand of $155.2 million at the end of the year, having completed a $20 million buyback.
Its price target for Nanosonics shares has increased from $3 to $3.75, compared with a share price of $2.88.
5 sentences from our version of the report,
chosen to cover it. Nothing here is written; every line is in the article below.
How
Summarized version
Nanosonics Ltd shares have fallen almost 30% over the past year, but according to the team at RBC Capital Markets, they could be primed for a recovery.
The report’s most important sentence, shortened and in plain words. How
Headline check
All two things this headline claims are in the report.
Figures, names and quoted words in the headline, looked for in the report itself — not in the summary above. How this is checked
The article, shortened and in plain language
Nanosonics Ltd shares have fallen almost 30% over the past year, but according to the team at RBC Capital Markets, they could be primed for a recovery.
The broking house has just released a new research report on the company and has assigned it an outperform rating and a share price target, to get to shortly.
First, let's look at the company's most recent news – its FY26 financial results and the announcement of a share buyback.
Nanosonics' main revenue-generating business at the moment is its Trophon division up 9%.
The company's revenue was up 3% to $203.9 million, while EBIT was $16 million, down 10%.
If the Trophon division is looked at on a stand-alone basis, its EBIT would be $50.6 million.
The company had no debt and cash on hand of $155.2 million at the end of the year, having completed a $20 million buyback.
Nanosonics also announced a new, $40 million buyback for FY27.
Chief Executive Officer Michael Kavanagh said:.
Its price target for Nanosonics shares has increased from $3 to $3.75, compared with a share price of $2.88.
Shortened to 1 minute
of reading, this version reads 10.3 on the Niral Score.
You are reading our version, not theirs.
This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with
verdicts and loaded words taken out. Plain description stays, and so do adjectives
that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations
are theirs — quotations are never edited — and the indicators beside it measure
this version. Hover or tap Adjectives to see every one left in the text.
How outlets headlined it
Each outlet's own headline. Struck through: the loaded words our version leaves out. Plainest first.
The Motley Fool AustraliaThis ASX biotech could jump more than 30%, one broker saysplain
The Motley Fool AustraliaCould this ASX biotech really jump more than 150%? One broker thinks so1 change
Readers can ask a question about this story here.
Questions and answers are for subscribers.
Sign in
to read them.
Comments are read before they appear where anything in them needs a person to look.
Nothing posted here is ever deleted; a comment taken down keeps its text and the reason,
so the decision can be looked at again. How this works